menu
    • menu
    [{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Series B Financing","leadProduct":"AGMB-101","moa":"MET receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"AgomAb Therapeutics N.V","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"AgomAb Therapeutics N.V \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"AgomAb Therapeutics N.V \/ Redmile Group"},{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"DT-001","moa":"TNF2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Dualyx","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Dualyx \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"5","companyTruncated":"Dualyx \/ Fountain Healthcare Partners"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dualyx

                            Belgium arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Dualyx

                            Belgium arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-001

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Fountain Healthcare Partners

                            Deal Size : $44.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Dualyx Raises 40 Million To Progress Treg Therapies For Autoimmune Diseases Into The Clinic

                            Details : The use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting the highly attractive TNF receptor 2 (TNFR2) and widely regarded as a master control switch in immune modulation, as well as its pipeline of Treg...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 15, 2023

                            Lead Product(s) : DT-001

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Fountain Healthcare Partners

                            Deal Size : $44.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-101

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $74.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators

                            Details : Proceeds to further advance lead compound AGMB-101 and expand pipeline in inflammatory, metabolic and fibrotic diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 10, 2021

                            Lead Product(s) : AGMB-101

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $74.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.